{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:36:10Z","timestamp":1793471770871,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Helmholtz-Zentrum Dresden - Rossendorf e.V."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Targeted alpha therapy represents an advanced and rapidly evolving form of precision cancer treatment with increasing importance in recent years. The alpha-emitter\n                      <jats:sup>225<\/jats:sup>\n                      Ac plays a key role in this clinical development due to its attractive physical and chemical properties. In this context, the macropa chelator has favorable characteristics in terms of labeling conditions and complex stability, making its derivatives exceptionally appealing for\n                      <jats:sup>225<\/jats:sup>\n                      Ac-labeling of heat-sensitive biomolecules. However, preclinical evaluation of such\n                      <jats:sup>225<\/jats:sup>\n                      Ac-containing molecules and comprehensive assessment of their pharmacokinetics, dosimetry and radiobiology necessitate a suitable diagnostic counterpart. Due to its attractive radiation properties,\n                      <jats:sup>133<\/jats:sup>\n                      La represents an adequate positron-emitting radionuclide to form a matched pair with\n                      <jats:sup>225<\/jats:sup>\n                      Ac for macropa-based radiopharmaceuticals. Herein, we describe the preparation and radiopharmacological characterization of macropa-functionalized,\n                      <jats:sup>133<\/jats:sup>\n                      La\/\n                      <jats:sup>225<\/jats:sup>\n                      Ac-labeled single-domain antibodies (sdAbs) targeting the epidermal growth factor receptor (EGFR) to demonstrate the general suitability of this theranostic pair of radionuclides.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The synthesis of a clickable, bicyclononyne-modified macropa chelator and its site-specific conjugation to azide-modified, monovalent and biparatopic sdAbs is presented. Subsequent labeling at room temperature (rt) for 15\u00a0min resulted in molar activities of 30 MBq\/nmol for\n                      <jats:sup>133<\/jats:sup>\n                      La and 0.5 MBq\/nmol for\n                      <jats:sup>225<\/jats:sup>\n                      Ac, respectively. In vitro studies using the\n                      <jats:sup>133<\/jats:sup>\n                      La-labeled sdAbs revealed comparable binding characteristics, but an enhanced cellular internalization of the biparatopic variant compared to its monovalent counterparts. This increased uptake consequently resulted in higher cytotoxicity of the\n                      <jats:sup>225<\/jats:sup>\n                      Ac-labeled biparatopic conjugate. In vivo PET imaging of the\n                      <jats:sup>133<\/jats:sup>\n                      La-labeled conjugates indicated comparable uptake and retention of the mono- and biparatopic variants in liver and kidneys, with the former showing slightly higher tumor accumulation. Ex vivo biodistribution studies conducted with\n                      <jats:sup>225<\/jats:sup>\n                      Ac-labeled conjugates largely confirmed the findings obtained by PET imaging, albeit with a marginally higher tumor accumulation of the biparatopic\n                      <jats:sup>225<\/jats:sup>\n                      Ac-radioimmunoconjugate. Final histological examinations of tumor and kidney tissues showed DNA damage in the renal cortex of the\n                      <jats:sup>225<\/jats:sup>\n                      Ac-radioimmunoconjugate-treated mice, but no differences in the number of \u03b3-H2AX-positive cells in the corresponding tumor tissues could be detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      We present a comprehensive study on the theranostic application of\n                      <jats:sup>133<\/jats:sup>\n                      La and\n                      <jats:sup>225<\/jats:sup>\n                      Ac for antibody-based biomolecules and lay the foundation for the future application of this matched pair of radionuclides towards labeling of heat-sensitive, macropa-functionalized radiopharmaceuticals in general.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41181-025-00354-7","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T02:59:40Z","timestamp":1750301980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["It\u2019s a match: use of the radionuclide theranostic pair 133La\/225Ac for the radiopharmacological characterization of EGFR-targeted single-domain antibodies"],"prefix":"10.1186","volume":"10","author":[{"given":"Johanna","family":"Trommer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6104-6676","authenticated-orcid":false,"given":"Martin","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5203-0776","authenticated-orcid":false,"given":"Falco","family":"Reissig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-6858","authenticated-orcid":false,"given":"Santiago Andres","family":"Br\u00fchlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Kathrin","family":"Nitt-Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7716-2142","authenticated-orcid":false,"given":"Zbynek","family":"Novy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3078-0907","authenticated-orcid":false,"given":"Katarina","family":"Hajduova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-3131","authenticated-orcid":false,"given":"Daniela","family":"Kurfurstova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7272-6260","authenticated-orcid":false,"given":"Romana","family":"Hendrychova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4842-1720","authenticated-orcid":false,"given":"Jan","family":"Bouchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1334-5916","authenticated-orcid":false,"given":"Milos","family":"Petrik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0646-5808","authenticated-orcid":false,"given":"Christin","family":"Neuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-9925","authenticated-orcid":false,"given":"Wiebke","family":"Sihver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-5330","authenticated-orcid":false,"given":"Sven","family":"Stadlbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1610-1493","authenticated-orcid":false,"given":"Jens","family":"Pietzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2424-3202","authenticated-orcid":false,"given":"Martin","family":"Kreller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-1271","authenticated-orcid":false,"given":"Klaus","family":"Kopka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-3186","authenticated-orcid":false,"given":"Constantin","family":"Mamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7571-4732","authenticated-orcid":false,"given":"Kristof","family":"Zarschler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"issue":"1","key":"354_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.33611\/trs.2_1","volume":"2","author":"H Akiba","year":"2020","unstructured":"Akiba H, Tsumoto K. Development and activities, including Immunocomplex formation, of biparatopic antibodies and alternative scaffold proteins. Translational Regul Sci. 2020;2(1):1\u20136.","journal-title":"Translational Regul Sci"},{"issue":"6","key":"354_CR2","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s11307-019-01320-x","volume":"21","author":"I Beltran Hernandez","year":"2019","unstructured":"Beltran Hernandez I, Rompen R, Rossin R, Xenaki KT, Katrukha EA, Nicolay K, van Bergen En Henegouwen P, Grull H, Oliveira S. Imaging of tumor spheroids, Dual-Isotope SPECT, and autoradiographic analysis to assess the tumor uptake and distribution of different nanobodies. Mol Imaging Biol. 2019;21(6):1079\u201388.","journal-title":"Mol Imaging Biol"},{"issue":"7","key":"354_CR3","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.7150\/thno.96403","volume":"14","author":"AP Bidkar","year":"2024","unstructured":"Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF, Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. Theranostics. 2024;14(7):2969\u201392.","journal-title":"Theranostics"},{"issue":"50","key":"354_CR4","doi-asserted-by":"publisher","first-page":"20699","DOI":"10.1021\/acs.inorgchem.3c01983","volume":"62","author":"MK Blei","year":"2023","unstructured":"Blei MK, Waurick L, Reissig F, Kopka K, Stumpf T, Drobot B, Kretzschmar J, Mamat C. Equilibrium thermodynamics of Macropa complexes with selected metal isotopes of radiopharmaceutical interest. Inorg Chem. 2023;62(50):20699\u2013709.","journal-title":"Inorg Chem"},{"issue":"8","key":"354_CR5","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","volume":"19","author":"L Bodei","year":"2022","unstructured":"Bodei L, Herrmann K, Schoder H, Scott AM, Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. Nat Rev Clin Oncol. 2022;19(8):534\u201350.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"354_CR6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1021\/acs.jmedchem.1c01791","volume":"65","author":"F Brandt","year":"2022","unstructured":"Brandt F, Ullrich M, Laube M, Kopka K, Bachmann M, L\u00f6ser R, Pietzsch J, Pietzsch HJ, van den Hoff J, Wodtke R. Clickable albumin binders for modulating the tumor uptake of targeted radiopharmaceuticals. J Med Chem. 2022;65(1):710\u201333.","journal-title":"J Med Chem"},{"key":"354_CR7","doi-asserted-by":"crossref","unstructured":"Br\u00fchlmann SA, Kreller M, Pietzsch HJ, Kopka K, Mamat C, Walther M, Reissig F. Efficient production of the PET radionuclide 133La for theranostic purposes in targeted alpha therapy using the 134Ba(p,2n)133La reaction. Pharmaceuticals (Basel). 2022;15(10):1167.","DOI":"10.3390\/ph15101167"},{"issue":"1","key":"354_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s41181-024-00292-w","volume":"9","author":"SA Br\u00fchlmann","year":"2024","unstructured":"Br\u00fchlmann SA, Walther M, Blei MK, Mamat C, Kopka K, Freudenberg R, Kreller M. Scalability study on [133La]LaCl3 production with a focus on potential clinical applications. EJNMMI Radiopharm Chem. 2024;9(1):60.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"4","key":"354_CR9","doi-asserted-by":"publisher","first-page":"e220157","DOI":"10.1148\/rycan.220157","volume":"5","author":"BJ Burkett","year":"2023","unstructured":"Burkett BJ, Bartlett DJ, McGarrah PW, Lewis AR, Johnson DR, Berberoglu K, Pandey MK, Packard AT, Halfdanarson TR, Hruska CB. Johnson GB and Kendi AT. A review of theranostics: perspectives on emerging approaches and clinical advancements. Radiol Imaging Cancer. 2023;5(4):e220157.","journal-title":"Radiol Imaging Cancer"},{"issue":"3","key":"354_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.23736\/S1824-4785.20.03266-5","volume":"64","author":"D Castillo Seoane","year":"2020","unstructured":"Castillo Seoane D, de Saint-Hubert M, Crabbe M, Struelens L, Koole M. Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225. Q J Nucl Med Mol Imaging. 2020;64(3):265\u201377.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"47","key":"354_CR11","doi-asserted-by":"publisher","first-page":"21555","DOI":"10.1021\/jacs.2c08438","volume":"144","author":"P Cieslik","year":"2022","unstructured":"Cieslik P, Kubeil M, Zarschler K, Ullrich M, Brandt F, Anger K, Wadepohl H, Kopka K, Bachmann M, Pietzsch J, Stephan H. Comba P. Toward personalized medicine: one Chelator for imaging and therapy with Lutetium-177 and Actinium-225. J Am Chem Soc. 2022;144(47):21555\u201367.","journal-title":"J Am Chem Soc"},{"issue":"6","key":"354_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s11307-023-01857-y","volume":"25","author":"RP Coll","year":"2023","unstructured":"Coll RP, Bright SJ, Martinus DKJ, Georgiou DK, Sawakuchi GO, Manning HC. Alpha Particle-Emitting radiopharmaceuticals as Cancer therapy: biological basis, current status, and future outlook for therapeutics discovery. Mol Imaging Biol. 2023;25(6):991\u20131019.","journal-title":"Mol Imaging Biol"},{"key":"354_CR13","doi-asserted-by":"crossref","unstructured":"Currie GM, Rohren EM. Sharpening the blade of precision theranostics. Semin Nucl Med. 2025.","DOI":"10.1053\/j.semnuclmed.2025.01.007"},{"key":"354_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.jconrel.2019.11.014","volume":"317","author":"P Debie","year":"2020","unstructured":"Debie P, Lafont C, Defrise M, Hansen I, van Willigen DM, van Leeuwen FWB, Gijsbers R, D\u2019Huyvetter M, Devoogdt N, Lahoutte T, Mollard P, Hernot S. Size and affinity kinetics of nanobodies influence targeting and penetration of solid tumours. J Control Release. 2020;317:34\u201342.","journal-title":"J Control Release"},{"issue":"49","key":"354_CR15","doi-asserted-by":"publisher","first-page":"9422","DOI":"10.1002\/anie.201003761","volume":"49","author":"J Dommerholt","year":"2010","unstructured":"Dommerholt J, Schmidt S, Temming R, Hendriks LJ, Rutjes FP, van Hest JC, Lefeber DJ, Friedl P, van Delft FL. Readily accessible bicyclononynes for bioorthogonal labeling and three-dimensional imaging of living cells. Angew Chem Int Ed Engl. 2010;49(49):9422\u20135.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"354_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-021-00666-5","volume":"6","author":"J Fan","year":"2021","unstructured":"Fan J, Zhuang X, Yang X, Xu Y, Zhou Z, Pan L, Chen S. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Signal Transduct Target Ther. 2021;6(1):320.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"354_CR17","first-page":"1191","volume":"31","author":"K Fujimori","year":"1990","unstructured":"Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med. 1990;31(7):1191\u20138.","journal-title":"J Nucl Med"},{"issue":"5","key":"354_CR19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.2967\/jnumed.107.048538","volume":"49","author":"LO Gainkam","year":"2008","unstructured":"Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, Vanhove C, Revets H, De Baetselier P, Lahoutte T. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT\/micro-CT. J Nucl Med. 2008;49(5):788\u201395.","journal-title":"J Nucl Med"},{"issue":"2","key":"354_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cmmi.408","volume":"6","author":"LO Gainkam","year":"2011","unstructured":"Gainkam LO, Caveliers V, Devoogdt N, Vanhove C, Xavier C, Boerman O, Muyldermans S, Bossuyt A, Lahoutte T. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging. 2011a;6(2):85\u201392.","journal-title":"Contrast Media Mol Imaging"},{"issue":"5","key":"354_CR20","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s11307-010-0428-4","volume":"13","author":"LO Gainkam","year":"2011","unstructured":"Gainkam LO, Keyaerts M, Caveliers V, Devoogdt N, Vanhove C, Van Grunsven L, Muyldermans S, Lahoutte T. Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. Mol Imaging Biol. 2011b;13(5):940\u20138.","journal-title":"Mol Imaging Biol"},{"issue":"Pt 21","key":"354_CR21","first-page":"4900","volume":"126","author":"R Heukers","year":"2013","unstructured":"Heukers R, Vermeulen JF, Fereidouni F, Bader AN, Voortman J, Roovers RC, Gerritsen HC, van Bergen En Henegouwen PM. Endocytosis of EGFR requires its kinase activity and N-terminal transmembrane dimerization motif. J Cell Sci. 2013;126(Pt 21):4900\u201312.","journal-title":"J Cell Sci"},{"issue":"1","key":"354_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41181-024-00239-1","volume":"9","author":"EL Hooijman","year":"2024","unstructured":"Hooijman EL, Radchenko V, Ling SW, Konijnenberg M, Brabander T, Koolen SLW, de Blois E. Implementing Ac-225 labelled radiopharmaceuticals: practical considerations and (pre-)clinical perspectives. EJNMMI Radiopharm Chem. 2024;9(1):9.","journal-title":"EJNMMI Radiopharm Chem"},{"issue":"3","key":"354_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11307-008-0133-8","volume":"10","author":"L Huang","year":"2008","unstructured":"Huang L, Gainkam LO, Caveliers V, Vanhove C, Keyaerts M, De Baetselier P, Bossuyt A, Revets H, Lahoutte T. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008;10(3):167\u201375.","journal-title":"Mol Imaging Biol"},{"key":"354_CR24","doi-asserted-by":"crossref","unstructured":"Hurley K, Cao M, Huang H, Wang Y. Targeted alpha therapy (TAT) with Single-Domain antibodies (Nanobodies). Cancers (Basel). 2023;15(13):3493.","DOI":"10.3390\/cancers15133493"},{"key":"354_CR25","doi-asserted-by":"crossref","unstructured":"Jang A, Kendi AT, Johnson GB, Halfdanarson TR, Sartor O. Targeted Alpha-Particle therapy: A review of current trials. Int J Mol Sci. 2023;24(14):11626.","DOI":"10.3390\/ijms241411626"},{"key":"354_CR26","doi-asserted-by":"crossref","unstructured":"Jovcevska I, Muyldermans S. Therapeutic Potential Nanobodies BioDrugs. 2020;34(1):11\u201326.","DOI":"10.1007\/s40259-019-00392-z"},{"issue":"9","key":"354_CR27","doi-asserted-by":"publisher","first-page":"e2250024","DOI":"10.1002\/eji.202250024","volume":"53","author":"NA Jumapili","year":"2023","unstructured":"Jumapili NA, Zivalj M, Barthelmess RM, Raes G, De Groof TWM, Devoogdt N, Stijlemans B, Vincke C, Van Ginderachter JA. A few good reasons to use nanobodies for cancer treatment. Eur J Immunol. 2023;53(9):e2250024.","journal-title":"Eur J Immunol"},{"issue":"4 Suppl 1","key":"354_CR28","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.jmir.2019.05.008","volume":"50","author":"JG Jurcic","year":"2019","unstructured":"Jurcic JG. Targeted Alpha-Particle therapy for hematologic malignancies. J Med Imaging Radiat Sci. 2019;50(4 Suppl 1):S53\u20137.","journal-title":"J Med Imaging Radiat Sci"},{"issue":"19","key":"354_CR29","first-page":"5144","volume":"52","author":"M Juweid","year":"1992","unstructured":"Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, Weinstein JN. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52(19):5144\u201353.","journal-title":"Cancer Res"},{"issue":"6","key":"354_CR30","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1021\/acs.bioconjchem.2c00190","volume":"33","author":"KJ Kadassery","year":"2022","unstructured":"Kadassery KJ, King AP, Fayn S, Baidoo KE, MacMillan SN, Escorcia FE, Wilson JJ. H2BZmacropa-NCS: A bifunctional Chelator for Actinium-225 targeted alpha therapy. Bioconjug Chem. 2022;33(6):1222\u201331.","journal-title":"Bioconjug Chem"},{"issue":"4","key":"354_CR31","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/cbic.201900419","volume":"21","author":"J Karges","year":"2020","unstructured":"Karges J, Jakubaszek M, Mari C, Zarschler K, Goud B, Stephan H, Gasser G. Synthesis and characterization of an epidermal growth factor Receptor-Selective RuII Polypyridyl-Nanobody conjugate as a photosensitizer for photodynamic therapy. ChemBioChem. 2020;21(4):531\u201342.","journal-title":"ChemBioChem"},{"issue":"3","key":"354_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2967\/jnumed.109.070532","volume":"51","author":"MA Keenan","year":"2010","unstructured":"Keenan MA, Stabin MG, Segars WP, Fernald MJ. RADAR realistic animal model series for dose assessment. J Nucl Med. 2010;51(3):471\u20136.","journal-title":"J Nucl Med"},{"issue":"10","key":"354_CR33","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1021\/bc200151q","volume":"22","author":"SS Kelkar","year":"2011","unstructured":"Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011;22(10):1879\u2013903.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"354_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00259-021-05431-y","volume":"49","author":"AP King","year":"2021","unstructured":"King AP, Lin FI, Escorcia FE. Why bother with alpha particles? Eur J Nucl Med Mol Imaging. 2021;49(1):7\u201317.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"354_CR35","doi-asserted-by":"crossref","unstructured":"Kozempel J, Mokhodoeva O, Vlk M. Progress in targeted Alpha-Particle therapy. What we learned about recoils release from in vivo generators. Molecules. 2018;23(3):581.","DOI":"10.3390\/molecules23030581"},{"key":"354_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.nbt.2018.03.004","volume":"45","author":"A Krasniqi","year":"2018","unstructured":"Krasniqi A, Bialkowska M, Xavier C, Van der Jeught K, Muyldermans S, Devoogdt N, D\u2019Huyvetter M. Pharmacokinetics of radiolabeled dimeric SdAbs constructs targeting human CD20. N Biotechnol. 2018;45:69\u201379.","journal-title":"N Biotechnol"},{"issue":"6","key":"354_CR37","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.molonc.2016.02.005","volume":"10","author":"D Kurfurstova","year":"2016","unstructured":"Kurfurstova D, Bartkova J, Vrtel R, Mickova A, Burdova A, Majera D, Mistrik M, Kral M, Santer FR, Bouchal J, Bartek J. DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer. Mol Oncol. 2016;10(6):879\u201394.","journal-title":"Mol Oncol"},{"key":"354_CR38","doi-asserted-by":"crossref","unstructured":"Lepareur N, Ramee B, Mougin-Degraef M, Bourgeois M. Clinical advances and perspectives in targeted radionuclide therapy. Pharmaceutics. 2023;15(6):1733.","DOI":"10.3390\/pharmaceutics15061733"},{"key":"354_CR39","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.semcancer.2022.04.002","volume":"85","author":"E Levantini","year":"2022","unstructured":"Levantini E, Maroni G, Del Re M, Tenen DG. EGFR signaling pathway as therapeutic target in human cancers. Semin Cancer Biol. 2022;85:253\u201375.","journal-title":"Semin Cancer Biol"},{"key":"354_CR40","doi-asserted-by":"crossref","unstructured":"Li C, Wen B, Wang L, Feng H, Xia X, Ding Z, Gao B, Zhang Y, Lan. X. 99mTc-labeled single-domain antibody EG2 in targeting epidermal growth factor receptor: an in-vitro and mouse model in-vivo study. Nucl Med Commun. 2015;36(5):452\u201360.","DOI":"10.1097\/MNM.0000000000000264"},{"issue":"2","key":"354_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11523-018-0550-9","volume":"13","author":"M Makvandi","year":"2018","unstructured":"Makvandi M, Dupis E, Engle JW, Nortier FM, Fassbender ME, Simon S, Birnbaum ER, Atcher RW, John KD, Rixe O, Norenberg JP. Alpha-Emitters and targeted alpha therapy in oncology: from basic science to clinical investigations. Target Oncol. 2018;13(2):189\u2013203.","journal-title":"Target Oncol"},{"issue":"5546","key":"354_CR42","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.1064126","volume":"294","author":"MR McDevitt","year":"2001","unstructured":"McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, Wu K, Pellegrini V, Curcio MJ, Miederer M, Bander NH, Scheinberg DA. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294(5546):1537\u201340.","journal-title":"Science"},{"key":"354_CR43","doi-asserted-by":"crossref","unstructured":"Miederer M, Benesova-Schafer M, Mamat C, Kastner D, Pretze M, Michler E, Brogsitter C, Kotzerke J, Kopka K. Scheinberg DA and McDevitt MR. Alpha-Emitting radionuclides: current status and future perspectives. Pharmaceuticals (Basel). 2024;17(1):76.","DOI":"10.3390\/ph17010076"},{"issue":"3","key":"354_CR44","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2174\/1874471011666180502104524","volume":"11","author":"A Morgenstern","year":"2018","unstructured":"Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm. 2018;11(3):200\u20138.","journal-title":"Curr Radiopharm"},{"issue":"2","key":"354_CR45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1021\/acs.inorgchem.0c02432","volume":"60","author":"A Morgenstern","year":"2021","unstructured":"Morgenstern A, Lilley LM, Stein BW, Kozimor SA, Batista ER, Yang P. Computer-Assisted design of macrocyclic chelators for Actinium-225 radiotherapeutics. Inorg Chem. 2021;60(2):623\u201332.","journal-title":"Inorg Chem"},{"issue":"6","key":"354_CR46","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.brachy.2023.06.228","volume":"22","author":"F Mourtada","year":"2023","unstructured":"Mourtada F, Tomiyoshi K, Sims-Mourtada J, Mukai-Sasaki Y, Yagihashi T, Namiki Y, Murai T, Yang DJ, Inoue T. Actinium-225 targeted agents: where are we now?? Brachytherapy. 2023;22(6):697\u2013708.","journal-title":"Brachytherapy"},{"issue":"16","key":"354_CR47","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1158\/0008-5472.CAN-11-2994","volume":"72","author":"K Movahedi","year":"2012","unstructured":"Movahedi K, Schoonooghe S, Laoui D, Houbracken I, Waelput W, Breckpot K, Bouwens L, Lahoutte T, De Baetselier P, Raes G, Devoogdt N, Van Ginderachter JA. Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. Cancer Res. 2012;72(16):4165\u201377.","journal-title":"Cancer Res"},{"key":"354_CR48","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775\u201397.","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"354_CR51","doi-asserted-by":"publisher","first-page":"22203","DOI":"10.1038\/s41598-020-79198-x","volume":"10","author":"BJB Nelson","year":"2020","unstructured":"Nelson BJB, Wilson J, Andersson JD, Wuest F. High yield cyclotron production of a novel 133\/135La theranostic pair for nuclear medicine. Sci Rep. 2020;10(1):22203.","journal-title":"Sci Rep"},{"key":"354_CR49","doi-asserted-by":"crossref","unstructured":"Nelson BJB, Andersson JD, Wuest F, Radiolanthanum. Promising theranostic radionuclides for PET, alpha, and Auger-Meitner therapy. Nucl Med Biol. 2022a;110\u2013111:59\u201366.","DOI":"10.1016\/j.nucmedbio.2022.04.005"},{"issue":"4","key":"354_CR50","doi-asserted-by":"publisher","first-page":"584","DOI":"10.2967\/jnumed.121.262459","volume":"63","author":"BJB Nelson","year":"2022","unstructured":"Nelson BJB, Ferguson S, Wuest M, Wilson J, Duke MJM, Richter S, Soenke-Jans H, Andersson JD, Juengling F, Wuest F. First in vivo and Phantom imaging of Cyclotron-Produced 133La as a theranostic radionuclide for 225Ac and 135La. J Nucl Med. 2022b;63(4):584\u201390.","journal-title":"J Nucl Med"},{"key":"354_CR52","doi-asserted-by":"crossref","unstructured":"Nelson BJB, Wilson J, Andersson JD, Wuest F. Theranostic imaging surrogates for targeted alpha therapy: progress in production, purification, and applications. Pharmaceuticals (Basel). 2023;16(11):1622.","DOI":"10.3390\/ph16111622"},{"issue":"1","key":"354_CR53","doi-asserted-by":"publisher","first-page":"2310890","DOI":"10.1080\/19420862.2024.2310890","volume":"16","author":"DL Niquille","year":"2024","unstructured":"Niquille DL, Fitzgerald KM, Gera N. Biparatopic antibodies: therapeutic applications and prospects. MAbs. 2024;16(1):2310890.","journal-title":"MAbs"},{"issue":"1","key":"354_CR54","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1039\/C3CS60304K","volume":"43","author":"EW Price","year":"2014","unstructured":"Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43(1):260\u201390.","journal-title":"Chem Soc Rev"},{"key":"354_CR55","doi-asserted-by":"crossref","unstructured":"Reissig F, Bauer D, Zarschler K, Novy Z, Bendova K, Ludik MC, Kopka K, Pietzsch HJ, Petrik M, Mamat C. Towards targeted alpha therapy with Actinium-225: chelators for mild condition radiolabeling and targeting PSMA-A proof of concept study. Cancers (Basel). 2021;13(8):1974.","DOI":"10.3390\/cancers13081974"},{"issue":"17","key":"354_CR56","doi-asserted-by":"publisher","first-page":"7203","DOI":"10.7150\/thno.78043","volume":"12","author":"F Reissig","year":"2022","unstructured":"Reissig F, Zarschler K, Novy Z, Petrik M, Bendova K, Kurfurstova D, Bouchal J, Ludik MC, Brandt F, Kopka K, Khoylou M, Pietzsch HJ, Hajduch M, Mamat C. Modulating the Pharmacokinetic profile of Actinium-225-labeled macropa-derived radioconjugates by dual targeting of PSMA and albumin. Theranostics. 2022;12(17):7203\u201315.","journal-title":"Theranostics"},{"issue":"3","key":"354_CR57","doi-asserted-by":"publisher","first-page":"156","DOI":"10.2174\/1874471011666180416161908","volume":"11","author":"AKH Robertson","year":"2018","unstructured":"Robertson AKH, Ramogida CF, Schaffer P, Radchenko V. Development of 225Ac radiopharmaceuticals: TRIUMF perspectives and experiences. Curr Radiopharm. 2018;11(3):156\u201372.","journal-title":"Curr Radiopharm"},{"issue":"8","key":"354_CR58","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1002\/ijc.26145","volume":"129","author":"RC Roovers","year":"2011","unstructured":"Roovers RC, Vosjan MJ, Laeremans T, el Khoulati R, de Bruin RC, Ferguson KM, van Verkleij AJ. Dongen GA and Van Bergen En Henegouwen PM. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer. 2011;129(8):2013\u201324.","journal-title":"Int J Cancer"},{"key":"354_CR59","doi-asserted-by":"crossref","unstructured":"Roscher M, Bakos G, Benesova M. Atomic Nanogenerators in Targeted Alpha Therapies: Curie\u2019s Legacy in Modern Cancer Management. Pharmaceuticals (Basel). 2020;13(4):76.","DOI":"10.3390\/ph13040076"},{"issue":"2","key":"354_CR60","first-page":"155","volume":"24","author":"SI Rudnick","year":"2009","unstructured":"Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. 2009;24(2):155\u201361.","journal-title":"Cancer Biother Radiopharm"},{"issue":"6","key":"354_CR61","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/0008-5472.CAN-10-2277","volume":"71","author":"SI Rudnick","year":"2011","unstructured":"Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD, Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011;71(6):2250\u20139.","journal-title":"Cancer Res"},{"issue":"10","key":"354_CR62","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1158\/1535-7163.MCT-09-0195","volume":"8","author":"MM Schmidt","year":"2009","unstructured":"Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther. 2009;8(10):2861\u201371.","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"354_CR63","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.str.2013.05.008","volume":"21","author":"KR Schmitz","year":"2013","unstructured":"Schmitz KR, Bagchi A, van Roovers RC. Bergen En Henegouwen PM and Ferguson KM. Structural evaluation of EGFR Inhibition mechanisms for nanobodies\/vhh domains. Structure. 2013;21(7):1214\u201324.","journal-title":"Structure"},{"issue":"3","key":"354_CR64","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/1874471011666180426130058","volume":"11","author":"G Sgouros","year":"2018","unstructured":"Sgouros G, Hobbs R, Josefsson A. Dosimetry and radiobiology of Alpha-Particle emitting radionuclides. Curr Radiopharm. 2018;11(3):209\u201314.","journal-title":"Curr Radiopharm"},{"issue":"6","key":"354_CR65","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s12033-021-00317-8","volume":"63","author":"J Sharifi","year":"2021","unstructured":"Sharifi J, Khirehgesh MR, Akbari B, Soleymani B, Mansouri K. Hu7CG2: A novel humanized Anti-Epidermal growth factor receptor (EGFR) biparatopic nanobody. Mol Biotechnol. 2021;63(6):525\u201333.","journal-title":"Mol Biotechnol"},{"issue":"9","key":"354_CR66","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1002\/chem.201904654","volume":"26","author":"G Singh","year":"2020","unstructured":"Singh G, Zarschler K, Hunoldt S, Martinez IIS, Ruehl CL, Matterna M, Bergmann R, Mathe D, Hegedus N, Bachmann M, Comba P. Versatile Bispidine-Based bifunctional chelators for 64CuII -Labelling of biomolecules. Chemistry. 2020;26(9):1989\u20132001.","journal-title":"Chemistry"},{"issue":"46","key":"354_CR67","doi-asserted-by":"publisher","first-page":"14712","DOI":"10.1002\/anie.201709532","volume":"56","author":"NA Thiele","year":"2017","unstructured":"Thiele NA, Brown V, Kelly JM, Amor-Coarasa A, Jermilova U, MacMillan SN, Nikolopoulou A, Ponnala S, Ramogida CF, Robertson AKH, Rodriguez-Rodriguez C, Schaffer P, Williams C Jr., Babich JW, Radchenko V, Wilson JJ. An Eighteen-Membered macrocyclic ligand for Actinium-225 targeted alpha therapy. Angew Chem Int Ed Engl. 2017;56(46):14712\u20137.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"354_CR68","first-page":"57","volume":"29","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29(2):57\u201361.","journal-title":"Trends Pharmacol Sci"},{"key":"354_CR69","doi-asserted-by":"publisher","first-page":"122593","DOI":"10.1016\/j.lfs.2024.122593","volume":"345","author":"RK Tripathy","year":"2024","unstructured":"Tripathy RK, Pande AH. Molecular and functional insight into anti-EGFR nanobody: theranostic implications for malignancies. Life Sci. 2024;345:122593.","journal-title":"Life Sci"},{"key":"354_CR70","doi-asserted-by":"crossref","unstructured":"Tronchin S, Forster JC, Hickson K, Bezak E. Dosimetry in targeted alpha therapy. A systematic review: current findings and what is needed. Phys Med Biol. 2022;67(9).","DOI":"10.1088\/1361-6560\/ac5fe0"},{"issue":"5","key":"354_CR71","doi-asserted-by":"publisher","first-page":"650","DOI":"10.7150\/thno.14479","volume":"6","author":"M Ullrich","year":"2016","unstructured":"Ullrich M, Bergmann R, Peitzsch M, Zenker EF, Cartellieri M, Bachmann M, Ehrhart-Bornstein M, Block NL, Schally AV, Eisenhofer G, Bornstein SR, Pietzsch J, Ziegler CG. Multimodal somatostatin receptor theranostics using [(64)Cu]Cu-\/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a mouse pheochromocytoma model. Theranostics. 2016;6(5):650\u201365.","journal-title":"Theranostics"},{"issue":"3","key":"354_CR72","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cpet.2021.03.011","volume":"16","author":"N Vahidfar","year":"2021","unstructured":"Vahidfar N, Eppard E, Farzanehfar S, Yordanova A, Fallahpoor M, Ahmadzadehfar H. An impressive approach in nuclear medicine: theranostics. PET Clin. 2021;16(3):327\u201340.","journal-title":"PET Clin"},{"key":"354_CR73","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-7219-7_1","volume":"1652","author":"Z Wang","year":"2017","unstructured":"Wang Z. ErbB receptors and Cancer. Methods Mol Biol. 2017;1652:3\u201335.","journal-title":"Methods Mol Biol"},{"issue":"9 Suppl","key":"354_CR74","first-page":"s2747","volume":"52","author":"JN Weinstein","year":"1992","unstructured":"Weinstein JN, van Osdol W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the binding site barrier. Cancer Res. 1992;52(9 Suppl):s2747\u201351.","journal-title":"Cancer Res"},{"issue":"13","key":"354_CR75","doi-asserted-by":"publisher","first-page":"6293","DOI":"10.7150\/thno.57177","volume":"11","author":"JM White","year":"2021","unstructured":"White JM, Escorcia FE, Viola NT. Perspectives on metals-based radioimmunotherapy (RIT): moving forward. Theranostics. 2021;11(13):6293\u2013314.","journal-title":"Theranostics"},{"key":"354_CR76","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3389\/fimmu.2017.01287","volume":"8","author":"KT Xenaki","year":"2017","unstructured":"Xenaki KT, Oliveira S, van Bergen En Henegouwen PMP. Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors. Front Immunol. 2017;8:1287.","journal-title":"Front Immunol"},{"issue":"50","key":"354_CR77","doi-asserted-by":"publisher","first-page":"11435","DOI":"10.1002\/chem.202002999","volume":"26","author":"H Yang","year":"2020","unstructured":"Yang H, Zhang C, Yuan Z, Rodriguez-Rodriguez C, Robertson A, Radchenko V, Perron R, Gendron D, Causey P, Gao F, Benard F, Schaffer P. Synthesis and evaluation of a macrocyclic Actinium-225 chelator, quality control and in vivo evaluation of 225Ac-crown-alphaMSH peptide. Chemistry. 2020;26(50):11435\u201340.","journal-title":"Chemistry"},{"key":"354_CR79","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1475-2859-12-97","volume":"12","author":"K Zarschler","year":"2013","unstructured":"Zarschler K, Witecy S, Kapplusch F, Foerster C, Stephan H. High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli. Microb Cell Fact. 2013;12:97.","journal-title":"Microb Cell Fact"},{"issue":"11","key":"354_CR78","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1039\/C4NR00595C","volume":"6","author":"K Zarschler","year":"2014","unstructured":"Zarschler K, Prapainop K, Mahon E, Rocks L, Bramini M, Kelly PM, Stephan H, Dawson KA. Diagnostic nanoparticle targeting of the EGF-receptor in complex biological conditions using single-domain antibodies. Nanoscale. 2014;6(11):6046\u201356.","journal-title":"Nanoscale"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00354-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00354-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00354-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:41:57Z","timestamp":1781606517000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41181-025-00354-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["354"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00354-7","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been updated to amend the license information","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animal experiments using\n                      133\n                      La-labeled compounds were carried out according to the guidelines of the German Regulations for Animal Welfare. The protocols were approved by the local Ethical Committee for Animal Experiments (license 25-5131\/562\/52). All animal experiments using\n                      225\n                      Ac-labeled compounds were performed in accordance with appropriate legal norms (Czech Law No. 246\/1992) and with the approval of the Ministry of Education, Youth and Sports (MSMT-35035\/2019-3) and approval of the Ethical committee of Faculty of Medicine and Dentistry, Palacky University in Olomouc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}